Skip to contentV
VitaNova Life Sciences Corp
V
VNOVVitaNova Life Sciences Corp Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$544.59K$544.59Kderived+18,053.1% vs Q4 2023 Net Income$167.92K$167.92KderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
VitaNova Life Sciences Corp · CIK 1699709 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$351,611— Operating Incomederived$232,683— Operating Cash Flowderived-$191,185N/M Margins · derivedGross margin64.6%
Operating margin42.7%
Net margin30.8%+177.0 pt vs Q4 2023
ended Apr 30, 2024 · filed Jul 29, 2024 · 90 d after period end